Brisbane, California
United States
27
2021-06-10
27
2024-05-14
These are the the leading inventors for applications assigned to UNITY BIOTECHNOLOGY, INC.:
UNITY BIOTECHNOLOGY, INC. based in Brisbane, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
Treating liver disease by selectively eliminating senescent cells
#2 | 2021-06-10 ✅ Patent 11,963,957 granted on 2024-04-23Treating cardiovascular disease by selectively eliminating senescent cells
#3 | 2020-09-17 ✅ Patent 11,111,259 granted on 2021-09-07Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
#4 | 2020-01-02 ✅ Patent 10,519,197 granted on 2019-12-31Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
#5 | 2019-12-19 ✅ Patent 10,717,722 granted on 2020-07-21Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
#6 | 2019-10-31 ✅ Patent 10,745,429 granted on 2020-08-18Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
#7 | 2019-10-31 ✅ Patent 10,738,042 granted on 2020-08-11Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
#8 | 2019-10-17 ✅ Patent 10,550,378 granted on 2020-02-04Composition comprising a gene vector that selectively depletes P16 positive senescent cells
#9 | 2019-05-23 ✅ Patent 10,588,916 granted on 2020-03-17Technology to inhibit vascular changes that lead to vision loss in the eye
#10 | 2019-05-09 ✅ Patent 10,378,002 granted on 2019-08-13Replication conditional virus that specifically kills senescent cells
#11 | 2019-01-24 ✅ Patent 10,328,073 granted on 2019-06-25Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells
#12 | 2018-12-20 ✅ Patent 10,329,279 granted on 2019-06-25Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use
#13 | 2018-10-25 ✅ Patent 10,478,433 granted on 2019-11-19Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss
#14 | 2018-09-13 ✅ Patent 10,413,542 granted on 2019-09-17Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase
#15 | 2018-09-06 ✅ Patent 10,517,866 granted on 2019-12-31Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor
#16 | 2018-08-23 ✅ Patent 10,478,432 granted on 2019-11-19Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye
#17 | 2018-08-23 ✅ Patent 10,258,618 granted on 2019-04-16Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen
#18 | 2018-07-12 ✅ Patent 10,426,788 granted on 2019-10-01Chemical entities that kill senescent cells for use in treating age-related disease
#19 | 2018-06-05 ✅ Patent 9,988,368 granted on 2018-06-05Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use
#20 | 2018-05-03 ✅ Patent 10,010,546 granted on 2018-07-03Treatment of ophthalmic conditions by selectively removing senescent cells from the eye
#21 | 2018-04-19 ✅ Patent 10,328,058 granted on 2019-06-25Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
#22 | 2017-12-07 ✅ Patent 9,980,962 granted on 2018-05-29Use of sulfonamide inhibitors of Bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary disease
#23 | 2017-11-16 ✅ Patent 10,130,628 granted on 2018-11-20Treatment of joint pain
#24 | 2017-08-10 ✅ Patent 9,993,472 granted on 2018-06-12Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
#25 | 2017-07-13 ✅ Patent 10,213,426 granted on 2019-02-26Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population
#26 | 2017-03-30 ✅ Patent 9,969,776 granted on 2018-05-15Drug conjugates for delivering compounds to senescent cells
#27 | 2016-02-11 ✅ Patent 10,279,018 granted on 2019-05-07Immunogenic compositions for inducing an immune response for elimination of senescent cells
Also check out Unity Biotechnology, Inc.'s (Brisbane, United States) applicant profile with 31 patent applications submitted.
538969 ⎘